nodes	percent_of_prediction	percent_of_DWPC	metapath
Pantoprazole—ABCG2—Leflunomide—systemic scleroderma	0.113	0.173	CbGbCtD
Pantoprazole—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.0876	0.134	CbGbCtD
Pantoprazole—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0696	0.107	CbGbCtD
Pantoprazole—CYP1A2—Pentoxifylline—systemic scleroderma	0.0487	0.0747	CbGbCtD
Pantoprazole—CYP1A2—Leflunomide—systemic scleroderma	0.0465	0.0713	CbGbCtD
Pantoprazole—ABCB1—Lisinopril—systemic scleroderma	0.0426	0.0654	CbGbCtD
Pantoprazole—CYP2C9—Leflunomide—systemic scleroderma	0.0419	0.0642	CbGbCtD
Pantoprazole—SLCO1B1—Methotrexate—systemic scleroderma	0.0351	0.0539	CbGbCtD
Pantoprazole—ABCB1—Captopril—systemic scleroderma	0.0319	0.0489	CbGbCtD
Pantoprazole—ABCG2—Methotrexate—systemic scleroderma	0.0279	0.0428	CbGbCtD
Pantoprazole—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0251	0.0385	CbGbCtD
Pantoprazole—CYP2C19—Prednisone—systemic scleroderma	0.0249	0.0382	CbGbCtD
Pantoprazole—ABCB1—Prednisone—systemic scleroderma	0.0201	0.0308	CbGbCtD
Pantoprazole—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.015	0.0231	CbGbCtD
Pantoprazole—CYP3A4—Prednisone—systemic scleroderma	0.012	0.0184	CbGbCtD
Pantoprazole—ABCB1—Methotrexate—systemic scleroderma	0.0101	0.0154	CbGbCtD
Pantoprazole—CYP2C9—cardial valve—systemic scleroderma	0.0084	0.456	CbGeAlD
Pantoprazole—ATP4B—digestive system—systemic scleroderma	0.00309	0.167	CbGeAlD
Pantoprazole—ATP4A—connective tissue—systemic scleroderma	0.00186	0.101	CbGeAlD
Pantoprazole—ATP4A—digestive system—systemic scleroderma	0.00134	0.0728	CbGeAlD
Pantoprazole—SLCO1B1—digestive system—systemic scleroderma	0.00072	0.039	CbGeAlD
Pantoprazole—ABCB1—blood vessel—systemic scleroderma	0.00053	0.0287	CbGeAlD
Pantoprazole—CYP2C19—digestive system—systemic scleroderma	0.000469	0.0254	CbGeAlD
Pantoprazole—CYP1A2—digestive system—systemic scleroderma	0.000383	0.0208	CbGeAlD
Pantoprazole—CYP2C9—digestive system—systemic scleroderma	0.000364	0.0197	CbGeAlD
Pantoprazole—ABCG2—lung—systemic scleroderma	0.000332	0.018	CbGeAlD
Pantoprazole—CYP1A2—lung—systemic scleroderma	0.00032	0.0173	CbGeAlD
Pantoprazole—CYP3A4—digestive system—systemic scleroderma	0.000277	0.015	CbGeAlD
Pantoprazole—ABCB1—digestive system—systemic scleroderma	0.000196	0.0106	CbGeAlD
Pantoprazole—ABCB1—lung—systemic scleroderma	0.000164	0.00889	CbGeAlD
Pantoprazole—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000328	CcSEcCtD
Pantoprazole—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000108	0.000328	CcSEcCtD
Pantoprazole—Myocardial infarction—Prednisone—systemic scleroderma	0.000108	0.000328	CcSEcCtD
Pantoprazole—Breast disorder—Methotrexate—systemic scleroderma	0.000108	0.000328	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000108	0.000327	CcSEcCtD
Pantoprazole—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000327	CcSEcCtD
Pantoprazole—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000108	0.000327	CcSEcCtD
Pantoprazole—Hypersensitivity—Azathioprine—systemic scleroderma	0.000108	0.000326	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000108	0.000326	CcSEcCtD
Pantoprazole—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000326	CcSEcCtD
Pantoprazole—Insomnia—Lisinopril—systemic scleroderma	0.000107	0.000325	CcSEcCtD
Pantoprazole—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000324	CcSEcCtD
Pantoprazole—Paraesthesia—Lisinopril—systemic scleroderma	0.000106	0.000323	CcSEcCtD
Pantoprazole—Vomiting—Captopril—systemic scleroderma	0.000106	0.000323	CcSEcCtD
Pantoprazole—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000321	CcSEcCtD
Pantoprazole—Dyspnoea—Lisinopril—systemic scleroderma	0.000106	0.00032	CcSEcCtD
Pantoprazole—Rash—Captopril—systemic scleroderma	0.000106	0.00032	CcSEcCtD
Pantoprazole—Dermatitis—Captopril—systemic scleroderma	0.000105	0.00032	CcSEcCtD
Pantoprazole—Somnolence—Lisinopril—systemic scleroderma	0.000105	0.000319	CcSEcCtD
Pantoprazole—Headache—Captopril—systemic scleroderma	0.000105	0.000318	CcSEcCtD
Pantoprazole—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000317	CcSEcCtD
Pantoprazole—Dyspepsia—Lisinopril—systemic scleroderma	0.000104	0.000316	CcSEcCtD
Pantoprazole—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000104	0.000315	CcSEcCtD
Pantoprazole—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000104	0.000315	CcSEcCtD
Pantoprazole—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000315	CcSEcCtD
Pantoprazole—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000315	CcSEcCtD
Pantoprazole—Asthma—Methotrexate—systemic scleroderma	0.000103	0.000314	CcSEcCtD
Pantoprazole—Infection—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000313	CcSEcCtD
Pantoprazole—Decreased appetite—Lisinopril—systemic scleroderma	0.000103	0.000312	CcSEcCtD
Pantoprazole—Eosinophilia—Methotrexate—systemic scleroderma	0.000102	0.00031	CcSEcCtD
Pantoprazole—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000102	0.00031	CcSEcCtD
Pantoprazole—Fatigue—Lisinopril—systemic scleroderma	0.000102	0.00031	CcSEcCtD
Pantoprazole—Shock—Mycophenolate mofetil—systemic scleroderma	0.000102	0.00031	CcSEcCtD
Pantoprazole—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000309	CcSEcCtD
Pantoprazole—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000308	CcSEcCtD
Pantoprazole—Hypersensitivity—Leflunomide—systemic scleroderma	0.000102	0.000308	CcSEcCtD
Pantoprazole—Pancreatitis—Methotrexate—systemic scleroderma	0.000101	0.000307	CcSEcCtD
Pantoprazole—Pain—Lisinopril—systemic scleroderma	0.000101	0.000307	CcSEcCtD
Pantoprazole—Constipation—Lisinopril—systemic scleroderma	0.000101	0.000307	CcSEcCtD
Pantoprazole—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000307	CcSEcCtD
Pantoprazole—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000306	CcSEcCtD
Pantoprazole—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.0001	0.000304	CcSEcCtD
Pantoprazole—Diarrhoea—Azathioprine—systemic scleroderma	0.0001	0.000303	CcSEcCtD
Pantoprazole—Haemoglobin—Prednisone—systemic scleroderma	9.96e-05	0.000302	CcSEcCtD
Pantoprazole—Nausea—Captopril—systemic scleroderma	9.94e-05	0.000301	CcSEcCtD
Pantoprazole—Abdominal discomfort—Methotrexate—systemic scleroderma	9.92e-05	0.000301	CcSEcCtD
Pantoprazole—Haemorrhage—Prednisone—systemic scleroderma	9.91e-05	0.0003	CcSEcCtD
Pantoprazole—Anorexia—Mycophenolate mofetil—systemic scleroderma	9.9e-05	0.0003	CcSEcCtD
Pantoprazole—Asthenia—Leflunomide—systemic scleroderma	9.9e-05	0.0003	CcSEcCtD
Pantoprazole—Hallucination—Prednisone—systemic scleroderma	9.86e-05	0.000299	CcSEcCtD
Pantoprazole—Pancytopenia—Methotrexate—systemic scleroderma	9.83e-05	0.000298	CcSEcCtD
Pantoprazole—Feeling abnormal—Lisinopril—systemic scleroderma	9.77e-05	0.000296	CcSEcCtD
Pantoprazole—Pruritus—Leflunomide—systemic scleroderma	9.76e-05	0.000296	CcSEcCtD
Pantoprazole—Connective tissue disorder—Prednisone—systemic scleroderma	9.74e-05	0.000295	CcSEcCtD
Pantoprazole—Hypotension—Mycophenolate mofetil—systemic scleroderma	9.71e-05	0.000294	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Lisinopril—systemic scleroderma	9.7e-05	0.000294	CcSEcCtD
Pantoprazole—Dysuria—Methotrexate—systemic scleroderma	9.68e-05	0.000293	CcSEcCtD
Pantoprazole—Dizziness—Azathioprine—systemic scleroderma	9.66e-05	0.000293	CcSEcCtD
Pantoprazole—Upper respiratory tract infection—Methotrexate—systemic scleroderma	9.62e-05	0.000291	CcSEcCtD
Pantoprazole—Erectile dysfunction—Methotrexate—systemic scleroderma	9.53e-05	0.000289	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	9.46e-05	0.000287	CcSEcCtD
Pantoprazole—Photosensitivity reaction—Methotrexate—systemic scleroderma	9.45e-05	0.000286	CcSEcCtD
Pantoprazole—Asthenia—Mycophenolic acid—systemic scleroderma	9.44e-05	0.000286	CcSEcCtD
Pantoprazole—Diarrhoea—Leflunomide—systemic scleroderma	9.44e-05	0.000286	CcSEcCtD
Pantoprazole—Urticaria—Lisinopril—systemic scleroderma	9.42e-05	0.000285	CcSEcCtD
Pantoprazole—Insomnia—Mycophenolate mofetil—systemic scleroderma	9.4e-05	0.000285	CcSEcCtD
Pantoprazole—Abdominal pain—Lisinopril—systemic scleroderma	9.37e-05	0.000284	CcSEcCtD
Pantoprazole—Body temperature increased—Lisinopril—systemic scleroderma	9.37e-05	0.000284	CcSEcCtD
Pantoprazole—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	9.33e-05	0.000283	CcSEcCtD
Pantoprazole—Pruritus—Mycophenolic acid—systemic scleroderma	9.31e-05	0.000282	CcSEcCtD
Pantoprazole—Vomiting—Azathioprine—systemic scleroderma	9.29e-05	0.000281	CcSEcCtD
Pantoprazole—Pneumonia—Methotrexate—systemic scleroderma	9.28e-05	0.000281	CcSEcCtD
Pantoprazole—Eye disorder—Prednisone—systemic scleroderma	9.26e-05	0.000281	CcSEcCtD
Pantoprazole—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	9.26e-05	0.000281	CcSEcCtD
Pantoprazole—Somnolence—Mycophenolate mofetil—systemic scleroderma	9.24e-05	0.00028	CcSEcCtD
Pantoprazole—Infestation NOS—Methotrexate—systemic scleroderma	9.23e-05	0.00028	CcSEcCtD
Pantoprazole—Infestation—Methotrexate—systemic scleroderma	9.23e-05	0.00028	CcSEcCtD
Pantoprazole—Rash—Azathioprine—systemic scleroderma	9.21e-05	0.000279	CcSEcCtD
Pantoprazole—Dermatitis—Azathioprine—systemic scleroderma	9.2e-05	0.000279	CcSEcCtD
Pantoprazole—Depression—Methotrexate—systemic scleroderma	9.2e-05	0.000279	CcSEcCtD
Pantoprazole—Flushing—Prednisone—systemic scleroderma	9.2e-05	0.000279	CcSEcCtD
Pantoprazole—Headache—Azathioprine—systemic scleroderma	9.15e-05	0.000277	CcSEcCtD
Pantoprazole—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	9.15e-05	0.000277	CcSEcCtD
Pantoprazole—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	9.14e-05	0.000277	CcSEcCtD
Pantoprazole—Dizziness—Leflunomide—systemic scleroderma	9.12e-05	0.000276	CcSEcCtD
Pantoprazole—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	9.03e-05	0.000274	CcSEcCtD
Pantoprazole—Diarrhoea—Mycophenolic acid—systemic scleroderma	9.01e-05	0.000273	CcSEcCtD
Pantoprazole—Stomatitis—Methotrexate—systemic scleroderma	8.99e-05	0.000272	CcSEcCtD
Pantoprazole—Conjunctivitis—Methotrexate—systemic scleroderma	8.97e-05	0.000272	CcSEcCtD
Pantoprazole—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	8.97e-05	0.000272	CcSEcCtD
Pantoprazole—Immune system disorder—Prednisone—systemic scleroderma	8.95e-05	0.000271	CcSEcCtD
Pantoprazole—Constipation—Mycophenolate mofetil—systemic scleroderma	8.88e-05	0.000269	CcSEcCtD
Pantoprazole—Pain—Mycophenolate mofetil—systemic scleroderma	8.88e-05	0.000269	CcSEcCtD
Pantoprazole—Arrhythmia—Prednisone—systemic scleroderma	8.85e-05	0.000268	CcSEcCtD
Pantoprazole—Sweating—Methotrexate—systemic scleroderma	8.85e-05	0.000268	CcSEcCtD
Pantoprazole—Haematuria—Methotrexate—systemic scleroderma	8.8e-05	0.000267	CcSEcCtD
Pantoprazole—Vomiting—Leflunomide—systemic scleroderma	8.77e-05	0.000266	CcSEcCtD
Pantoprazole—Alopecia—Prednisone—systemic scleroderma	8.76e-05	0.000265	CcSEcCtD
Pantoprazole—Hypersensitivity—Lisinopril—systemic scleroderma	8.74e-05	0.000265	CcSEcCtD
Pantoprazole—Hepatobiliary disease—Methotrexate—systemic scleroderma	8.73e-05	0.000264	CcSEcCtD
Pantoprazole—Dizziness—Mycophenolic acid—systemic scleroderma	8.7e-05	0.000264	CcSEcCtD
Pantoprazole—Epistaxis—Methotrexate—systemic scleroderma	8.7e-05	0.000264	CcSEcCtD
Pantoprazole—Rash—Leflunomide—systemic scleroderma	8.7e-05	0.000264	CcSEcCtD
Pantoprazole—Dermatitis—Leflunomide—systemic scleroderma	8.69e-05	0.000263	CcSEcCtD
Pantoprazole—Mental disorder—Prednisone—systemic scleroderma	8.68e-05	0.000263	CcSEcCtD
Pantoprazole—Nausea—Azathioprine—systemic scleroderma	8.68e-05	0.000263	CcSEcCtD
Pantoprazole—Headache—Leflunomide—systemic scleroderma	8.64e-05	0.000262	CcSEcCtD
Pantoprazole—Malnutrition—Prednisone—systemic scleroderma	8.63e-05	0.000261	CcSEcCtD
Pantoprazole—Agranulocytosis—Methotrexate—systemic scleroderma	8.61e-05	0.000261	CcSEcCtD
Pantoprazole—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	8.56e-05	0.000259	CcSEcCtD
Pantoprazole—Asthenia—Lisinopril—systemic scleroderma	8.51e-05	0.000258	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	8.49e-05	0.000257	CcSEcCtD
Pantoprazole—Pruritus—Lisinopril—systemic scleroderma	8.39e-05	0.000254	CcSEcCtD
Pantoprazole—Vomiting—Mycophenolic acid—systemic scleroderma	8.37e-05	0.000254	CcSEcCtD
Pantoprazole—Haemoglobin—Methotrexate—systemic scleroderma	8.33e-05	0.000252	CcSEcCtD
Pantoprazole—Rash—Mycophenolic acid—systemic scleroderma	8.3e-05	0.000251	CcSEcCtD
Pantoprazole—Dermatitis—Mycophenolic acid—systemic scleroderma	8.29e-05	0.000251	CcSEcCtD
Pantoprazole—Hepatitis—Methotrexate—systemic scleroderma	8.28e-05	0.000251	CcSEcCtD
Pantoprazole—Haemorrhage—Methotrexate—systemic scleroderma	8.28e-05	0.000251	CcSEcCtD
Pantoprazole—Urticaria—Mycophenolate mofetil—systemic scleroderma	8.25e-05	0.00025	CcSEcCtD
Pantoprazole—Headache—Mycophenolic acid—systemic scleroderma	8.25e-05	0.00025	CcSEcCtD
Pantoprazole—Pharyngitis—Methotrexate—systemic scleroderma	8.22e-05	0.000249	CcSEcCtD
Pantoprazole—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	8.21e-05	0.000249	CcSEcCtD
Pantoprazole—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	8.21e-05	0.000249	CcSEcCtD
Pantoprazole—Nausea—Leflunomide—systemic scleroderma	8.2e-05	0.000248	CcSEcCtD
Pantoprazole—Urinary tract disorder—Methotrexate—systemic scleroderma	8.18e-05	0.000248	CcSEcCtD
Pantoprazole—Vision blurred—Prednisone—systemic scleroderma	8.13e-05	0.000246	CcSEcCtD
Pantoprazole—Urethral disorder—Methotrexate—systemic scleroderma	8.12e-05	0.000246	CcSEcCtD
Pantoprazole—Diarrhoea—Lisinopril—systemic scleroderma	8.11e-05	0.000246	CcSEcCtD
Pantoprazole—Ill-defined disorder—Prednisone—systemic scleroderma	8.01e-05	0.000243	CcSEcCtD
Pantoprazole—Visual impairment—Methotrexate—systemic scleroderma	7.98e-05	0.000242	CcSEcCtD
Pantoprazole—Anaemia—Prednisone—systemic scleroderma	7.97e-05	0.000242	CcSEcCtD
Pantoprazole—Agitation—Prednisone—systemic scleroderma	7.93e-05	0.00024	CcSEcCtD
Pantoprazole—Angioedema—Prednisone—systemic scleroderma	7.88e-05	0.000239	CcSEcCtD
Pantoprazole—Dizziness—Lisinopril—systemic scleroderma	7.84e-05	0.000238	CcSEcCtD
Pantoprazole—Erythema multiforme—Methotrexate—systemic scleroderma	7.83e-05	0.000237	CcSEcCtD
Pantoprazole—Nausea—Mycophenolic acid—systemic scleroderma	7.82e-05	0.000237	CcSEcCtD
Pantoprazole—Malaise—Prednisone—systemic scleroderma	7.78e-05	0.000236	CcSEcCtD
Pantoprazole—Vertigo—Prednisone—systemic scleroderma	7.75e-05	0.000235	CcSEcCtD
Pantoprazole—Eye disorder—Methotrexate—systemic scleroderma	7.74e-05	0.000235	CcSEcCtD
Pantoprazole—Syncope—Prednisone—systemic scleroderma	7.74e-05	0.000234	CcSEcCtD
Pantoprazole—Tinnitus—Methotrexate—systemic scleroderma	7.72e-05	0.000234	CcSEcCtD
Pantoprazole—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	7.65e-05	0.000232	CcSEcCtD
Pantoprazole—Loss of consciousness—Prednisone—systemic scleroderma	7.58e-05	0.00023	CcSEcCtD
Pantoprazole—Vomiting—Lisinopril—systemic scleroderma	7.54e-05	0.000228	CcSEcCtD
Pantoprazole—Immune system disorder—Methotrexate—systemic scleroderma	7.48e-05	0.000227	CcSEcCtD
Pantoprazole—Rash—Lisinopril—systemic scleroderma	7.48e-05	0.000226	CcSEcCtD
Pantoprazole—Convulsion—Prednisone—systemic scleroderma	7.48e-05	0.000226	CcSEcCtD
Pantoprazole—Dermatitis—Lisinopril—systemic scleroderma	7.47e-05	0.000226	CcSEcCtD
Pantoprazole—Asthenia—Mycophenolate mofetil—systemic scleroderma	7.45e-05	0.000226	CcSEcCtD
Pantoprazole—Hypertension—Prednisone—systemic scleroderma	7.45e-05	0.000226	CcSEcCtD
Pantoprazole—Chills—Methotrexate—systemic scleroderma	7.43e-05	0.000225	CcSEcCtD
Pantoprazole—Headache—Lisinopril—systemic scleroderma	7.43e-05	0.000225	CcSEcCtD
Pantoprazole—Pruritus—Mycophenolate mofetil—systemic scleroderma	7.35e-05	0.000223	CcSEcCtD
Pantoprazole—Myalgia—Prednisone—systemic scleroderma	7.35e-05	0.000223	CcSEcCtD
Pantoprazole—Arthralgia—Prednisone—systemic scleroderma	7.35e-05	0.000223	CcSEcCtD
Pantoprazole—Anxiety—Prednisone—systemic scleroderma	7.32e-05	0.000222	CcSEcCtD
Pantoprazole—Alopecia—Methotrexate—systemic scleroderma	7.32e-05	0.000222	CcSEcCtD
Pantoprazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	7.29e-05	0.000221	CcSEcCtD
Pantoprazole—Discomfort—Prednisone—systemic scleroderma	7.26e-05	0.00022	CcSEcCtD
Pantoprazole—Mental disorder—Methotrexate—systemic scleroderma	7.26e-05	0.00022	CcSEcCtD
Pantoprazole—Malnutrition—Methotrexate—systemic scleroderma	7.21e-05	0.000218	CcSEcCtD
Pantoprazole—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	7.11e-05	0.000215	CcSEcCtD
Pantoprazole—Dysgeusia—Methotrexate—systemic scleroderma	7.06e-05	0.000214	CcSEcCtD
Pantoprazole—Nausea—Lisinopril—systemic scleroderma	7.04e-05	0.000213	CcSEcCtD
Pantoprazole—Anaphylactic shock—Prednisone—systemic scleroderma	7.04e-05	0.000213	CcSEcCtD
Pantoprazole—Oedema—Prednisone—systemic scleroderma	7.04e-05	0.000213	CcSEcCtD
Pantoprazole—Infection—Prednisone—systemic scleroderma	7e-05	0.000212	CcSEcCtD
Pantoprazole—Back pain—Methotrexate—systemic scleroderma	6.97e-05	0.000211	CcSEcCtD
Pantoprazole—Shock—Prednisone—systemic scleroderma	6.93e-05	0.00021	CcSEcCtD
Pantoprazole—Nervous system disorder—Prednisone—systemic scleroderma	6.91e-05	0.000209	CcSEcCtD
Pantoprazole—Tachycardia—Prednisone—systemic scleroderma	6.87e-05	0.000208	CcSEcCtD
Pantoprazole—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.87e-05	0.000208	CcSEcCtD
Pantoprazole—Skin disorder—Prednisone—systemic scleroderma	6.84e-05	0.000207	CcSEcCtD
Pantoprazole—Hyperhidrosis—Prednisone—systemic scleroderma	6.81e-05	0.000206	CcSEcCtD
Pantoprazole—Vision blurred—Methotrexate—systemic scleroderma	6.8e-05	0.000206	CcSEcCtD
Pantoprazole—Anorexia—Prednisone—systemic scleroderma	6.71e-05	0.000203	CcSEcCtD
Pantoprazole—Ill-defined disorder—Methotrexate—systemic scleroderma	6.69e-05	0.000203	CcSEcCtD
Pantoprazole—Anaemia—Methotrexate—systemic scleroderma	6.66e-05	0.000202	CcSEcCtD
Pantoprazole—Vomiting—Mycophenolate mofetil—systemic scleroderma	6.6e-05	0.0002	CcSEcCtD
Pantoprazole—Rash—Mycophenolate mofetil—systemic scleroderma	6.55e-05	0.000198	CcSEcCtD
Pantoprazole—Dermatitis—Mycophenolate mofetil—systemic scleroderma	6.54e-05	0.000198	CcSEcCtD
Pantoprazole—Headache—Mycophenolate mofetil—systemic scleroderma	6.51e-05	0.000197	CcSEcCtD
Pantoprazole—Malaise—Methotrexate—systemic scleroderma	6.5e-05	0.000197	CcSEcCtD
Pantoprazole—Vertigo—Methotrexate—systemic scleroderma	6.48e-05	0.000196	CcSEcCtD
Pantoprazole—Leukopenia—Methotrexate—systemic scleroderma	6.45e-05	0.000196	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Prednisone—systemic scleroderma	6.42e-05	0.000194	CcSEcCtD
Pantoprazole—Insomnia—Prednisone—systemic scleroderma	6.37e-05	0.000193	CcSEcCtD
Pantoprazole—Paraesthesia—Prednisone—systemic scleroderma	6.32e-05	0.000192	CcSEcCtD
Pantoprazole—Cough—Methotrexate—systemic scleroderma	6.29e-05	0.000191	CcSEcCtD
Pantoprazole—Convulsion—Methotrexate—systemic scleroderma	6.25e-05	0.000189	CcSEcCtD
Pantoprazole—Dyspepsia—Prednisone—systemic scleroderma	6.2e-05	0.000188	CcSEcCtD
Pantoprazole—Nausea—Mycophenolate mofetil—systemic scleroderma	6.17e-05	0.000187	CcSEcCtD
Pantoprazole—Myalgia—Methotrexate—systemic scleroderma	6.14e-05	0.000186	CcSEcCtD
Pantoprazole—Chest pain—Methotrexate—systemic scleroderma	6.14e-05	0.000186	CcSEcCtD
Pantoprazole—Arthralgia—Methotrexate—systemic scleroderma	6.14e-05	0.000186	CcSEcCtD
Pantoprazole—Decreased appetite—Prednisone—systemic scleroderma	6.12e-05	0.000185	CcSEcCtD
Pantoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	6.1e-05	0.000185	CcSEcCtD
Pantoprazole—Fatigue—Prednisone—systemic scleroderma	6.07e-05	0.000184	CcSEcCtD
Pantoprazole—Discomfort—Methotrexate—systemic scleroderma	6.07e-05	0.000184	CcSEcCtD
Pantoprazole—Constipation—Prednisone—systemic scleroderma	6.02e-05	0.000182	CcSEcCtD
Pantoprazole—Confusional state—Methotrexate—systemic scleroderma	5.93e-05	0.00018	CcSEcCtD
Pantoprazole—Anaphylactic shock—Methotrexate—systemic scleroderma	5.88e-05	0.000178	CcSEcCtD
Pantoprazole—Infection—Methotrexate—systemic scleroderma	5.85e-05	0.000177	CcSEcCtD
Pantoprazole—Feeling abnormal—Prednisone—systemic scleroderma	5.8e-05	0.000176	CcSEcCtD
Pantoprazole—Nervous system disorder—Methotrexate—systemic scleroderma	5.77e-05	0.000175	CcSEcCtD
Pantoprazole—Thrombocytopenia—Methotrexate—systemic scleroderma	5.76e-05	0.000175	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Prednisone—systemic scleroderma	5.76e-05	0.000174	CcSEcCtD
Pantoprazole—Skin disorder—Methotrexate—systemic scleroderma	5.72e-05	0.000173	CcSEcCtD
Pantoprazole—Hyperhidrosis—Methotrexate—systemic scleroderma	5.69e-05	0.000172	CcSEcCtD
Pantoprazole—Anorexia—Methotrexate—systemic scleroderma	5.61e-05	0.00017	CcSEcCtD
Pantoprazole—Urticaria—Prednisone—systemic scleroderma	5.59e-05	0.000169	CcSEcCtD
Pantoprazole—Body temperature increased—Prednisone—systemic scleroderma	5.57e-05	0.000169	CcSEcCtD
Pantoprazole—Abdominal pain—Prednisone—systemic scleroderma	5.57e-05	0.000169	CcSEcCtD
Pantoprazole—Hypotension—Methotrexate—systemic scleroderma	5.5e-05	0.000167	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	5.36e-05	0.000162	CcSEcCtD
Pantoprazole—Insomnia—Methotrexate—systemic scleroderma	5.32e-05	0.000161	CcSEcCtD
Pantoprazole—Paraesthesia—Methotrexate—systemic scleroderma	5.28e-05	0.00016	CcSEcCtD
Pantoprazole—Dyspnoea—Methotrexate—systemic scleroderma	5.25e-05	0.000159	CcSEcCtD
Pantoprazole—Somnolence—Methotrexate—systemic scleroderma	5.23e-05	0.000159	CcSEcCtD
Pantoprazole—Hypersensitivity—Prednisone—systemic scleroderma	5.19e-05	0.000157	CcSEcCtD
Pantoprazole—Dyspepsia—Methotrexate—systemic scleroderma	5.18e-05	0.000157	CcSEcCtD
Pantoprazole—Decreased appetite—Methotrexate—systemic scleroderma	5.12e-05	0.000155	CcSEcCtD
Pantoprazole—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.08e-05	0.000154	CcSEcCtD
Pantoprazole—Fatigue—Methotrexate—systemic scleroderma	5.07e-05	0.000154	CcSEcCtD
Pantoprazole—Asthenia—Prednisone—systemic scleroderma	5.05e-05	0.000153	CcSEcCtD
Pantoprazole—Pain—Methotrexate—systemic scleroderma	5.03e-05	0.000152	CcSEcCtD
Pantoprazole—Pruritus—Prednisone—systemic scleroderma	4.98e-05	0.000151	CcSEcCtD
Pantoprazole—Feeling abnormal—Methotrexate—systemic scleroderma	4.85e-05	0.000147	CcSEcCtD
Pantoprazole—Diarrhoea—Prednisone—systemic scleroderma	4.82e-05	0.000146	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.81e-05	0.000146	CcSEcCtD
Pantoprazole—Urticaria—Methotrexate—systemic scleroderma	4.68e-05	0.000142	CcSEcCtD
Pantoprazole—Dizziness—Prednisone—systemic scleroderma	4.66e-05	0.000141	CcSEcCtD
Pantoprazole—Body temperature increased—Methotrexate—systemic scleroderma	4.65e-05	0.000141	CcSEcCtD
Pantoprazole—Abdominal pain—Methotrexate—systemic scleroderma	4.65e-05	0.000141	CcSEcCtD
Pantoprazole—Vomiting—Prednisone—systemic scleroderma	4.48e-05	0.000136	CcSEcCtD
Pantoprazole—Rash—Prednisone—systemic scleroderma	4.44e-05	0.000135	CcSEcCtD
Pantoprazole—Dermatitis—Prednisone—systemic scleroderma	4.44e-05	0.000134	CcSEcCtD
Pantoprazole—Headache—Prednisone—systemic scleroderma	4.41e-05	0.000134	CcSEcCtD
Pantoprazole—Hypersensitivity—Methotrexate—systemic scleroderma	4.34e-05	0.000131	CcSEcCtD
Pantoprazole—Asthenia—Methotrexate—systemic scleroderma	4.22e-05	0.000128	CcSEcCtD
Pantoprazole—Nausea—Prednisone—systemic scleroderma	4.18e-05	0.000127	CcSEcCtD
Pantoprazole—Pruritus—Methotrexate—systemic scleroderma	4.16e-05	0.000126	CcSEcCtD
Pantoprazole—Diarrhoea—Methotrexate—systemic scleroderma	4.03e-05	0.000122	CcSEcCtD
Pantoprazole—Dizziness—Methotrexate—systemic scleroderma	3.89e-05	0.000118	CcSEcCtD
Pantoprazole—Vomiting—Methotrexate—systemic scleroderma	3.74e-05	0.000113	CcSEcCtD
Pantoprazole—Rash—Methotrexate—systemic scleroderma	3.71e-05	0.000112	CcSEcCtD
Pantoprazole—Dermatitis—Methotrexate—systemic scleroderma	3.71e-05	0.000112	CcSEcCtD
Pantoprazole—Headache—Methotrexate—systemic scleroderma	3.69e-05	0.000112	CcSEcCtD
Pantoprazole—Nausea—Methotrexate—systemic scleroderma	3.5e-05	0.000106	CcSEcCtD
